Standards & Regulation

What progress is being made in the development of novel drugs in neuroscience?

Mexico’s Customs and Armed Forces have seized a fake batch of the Sputnik V COVID-19 vaccine.

Craig Burton from the AAM says patients must be able to access generics and biosimilars.

Is pharma now ushering in a new era of precision in neuroscience R&D?

How can the FDA tackle the inspection backlog?

Sputnik V (finally and definitely) starts rolling review with the EMA.

How to add value and reduce risks with ethics.

We have vaccines. Now, pharma’s mission is to address novel variants. And vaccine hesitancy.

Cell and gene therapy manufacturing technologies and methods are advancing rapidly, but can regulators keep up?

Vaccine development for COVID-19 may have been rapid, but no one has scrimped on safety.